TD Cowen analyst Tyler Van Buren has maintained their bullish stance on KROS stock, giving a Buy rating on November 5. Tyler Van Buren has ...
greater potency compared to an anti-ActRII antibody, and most recently an increase in lean mass and lowered fat mass gain following treatment with metformin and SRK-439. Turning to Slide 16, we ...
BYM388 – also known as bimagrumab – is an antibody targeting the myostatin/Activin type II receptor (ActRII) pathway and has been given a breakthrough designation by the US FDA for IBM.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback